application): The single specific aim of this Phase I proposal is to test the hypothesis that the potent kallikrein inhibitor EPI-K503 can prevent and/or treat PG-APS-induced inflammatory arthritis and its associated systemic inflammation. The rationale for this proposal is that specific inhibition of the enzyme kallikrein will block its effects to worsen inflammatory changes. The planned inhibitor is a peptide analogous to aprotinin that will be injected into an established rat model of acute and chronic relapsing inflammatory erosive arthritis, with appropriate controls. Inflammatory changes in joints and systemic measures of inflammation will be assessed. If the inhibitor is successful in decreasing the arthritis and systemic inflammation, there are plans for a Phase II study to develop non-peptide inhibitors of the enzyme with related structures, and to test these in a model of inflammatory bowel disease.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
3R41AR045848-01S1
Application #
6228639
Study Section
Special Emphasis Panel (ZRG3 (01))
Program Officer
Serrate-Sztein, Susana
Project Start
1999-09-10
Project End
2000-09-09
Budget Start
1999-09-10
Budget End
2000-09-09
Support Year
1
Fiscal Year
2000
Total Cost
$50,562
Indirect Cost
Name
Dyax Corporation
Department
Type
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139